Arrowstreet Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Arrowstreet Capital’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.4M	Sell	1,642,086 -681,178	-29%	-$24.7M	0.03%	467
2026 Q1	$70.8M	Buy	2,323,264 +617,364	+36%	+$20.4M	0.04%	399
2025 Q4	$61.2M	Buy	+1,705,900	New	+$52.1M	0.04%	418
2024 Q3	–	Sell	-179,497	Closed	-$2.83M	–	1793
2024 Q2	$2.83M	Sell	179,497 -147,652	-45%	-$2.66M	﹤0.01%	985
2024 Q1	$7M	Buy	327,149 +284,489	+667%	+$5.34M	0.01%	796
2023 Q4	$644K	Sell	42,660 -291,876	-87%	-$5.18M	﹤0.01%	1185
2023 Q3	$7.26M	Sell	334,536 -123,221	-27%	-$2.81M	0.01%	593
2023 Q2	$10.6M	Buy	+457,757	New	+$10.5M	0.01%	500

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's INDV Position: Q2 2026 in Review

Arrowstreet Capital reduced its Indivior Pharmaceuticals (INDV) stake by 29% in Q2 2026, selling an estimated $24.7M and leaving 1,642,086 shares worth $67.4M. The position accounts for 0.03% of the portfolio, ranked #467.

Arrowstreet Capital first reported a position in INDV in Q2 2023 and has held it in 8 quarters since. The position peaked at $70.8M in Q1 2026. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Arrowstreet Capital held 1,642,086 shares of Indivior Pharmaceuticals worth $67.4M as of Q2 2026.
Arrowstreet Capital sold 681,178 Indivior Pharmaceuticals shares in Q2 2026, an estimated $24.7M.
Indivior Pharmaceuticals made up 0.03% of Arrowstreet Capital's portfolio in Q2 2026, its #467 holding.
Arrowstreet Capital first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
Arrowstreet Capital's Indivior Pharmaceuticals position peaked at $70.8M in Q1 2026.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.